Chinese Physicians Believe That HCV Incidence May Be Increasing in China With Blood Transfusion Thought to Be the Dominant HCV Transmission Route
Chinese Physicians Believe That HCV Incidence May Be Increasing in China With
Blood Transfusion Thought to Be the Dominant HCV Transmission Route
Research and Markets (http://www.researchandmarkets.com/reports/c33734) has
announced the addition of Hepatitis in China - Liver Let Die? to their offering.
Hepatitis is a major health problem in China, which is home to one third of
hepatitis B patients and one quarter of hepatitis C patients globally. HBV
vaccination, together with HBV and HCV screening have helped to reduce
transmission, but continued transmission from mother to child (for HBV) and
transmission via blood transfusions (HCV) means that HBV and HCV are likely to
remain a problem.
This report provides an analysis of the current dynamics of the Chinese
hepatitis market through primary research data from 176 physicians, supported by
key opinion leaders. It identifies drivers and resistors of the Chinese
hepatitis market, and how the Chinese healthcare system impacts these
market-shaping factors. The report also provides an examination of key hepatitis
drug regimens for hepatitis in China, and factors affecting prescription trends
underlying these regimens. An assessment of the differences between China and
the 7 major markets in terms of HBV and HCV transmission and diagnosis is
provided.
This physician research indicated that HBV incidence is decreasing in China. In
contrast to the seven major markets, where most patients acquire HBV sexually,
perinatal transmission is the dominant HBV transmission route, which impacts on
HBV disease progression and effectiveness of drug therapy.
Chinese physicians believe that HCV incidence may be increasing in China. Blood
transfusion is though to be the dominant HCV transmission route in China, while
in the seven major markets, HCV is mainly acquired through intravenous drug use.
Chinese physicians do not consider any HBV therapy a gold-standard, although
lamivudine is the most prescribed first-line therapy, while adefovir is the most
prescribed second-line therapy. While treatment choice is more limited for HCV,
the Chinese HCV market is highly fragmented, with treatment differing
significantly between regions.
Reasons to read this report:
-- Review the clinical and commercial factors shaping the uptake of hepatitis
products in China, and the opportunities and threats facing the market
-- Gain insight into HBV and HCV prevalence, transmission and co-infection in
China
-- Evaluate unmet needs in China's hepatitis market and capitalize on these
opportunities to develop commercial strategies to increase market penetration
Key topics covered:
-- Insight into the Chinese Hepatitis B & C market
-- Coverage of the Stakeholder Insight Survey
-- China: an overview
-- Etiology & epidemiology
-- Diagnosis rates and presentation
-- Treatment options
-- Valuing the Chinese hepatitis market: threats, drivers and the future
-- Opinion Leader Transcripts
For more information visit http://www.researchandmarkets.com/reports/c33734
Source: Datamonitor
Source: Business Wire
http://www.redorbit.com/news/health/408883/chinese_physicians_believe_that_hcv_i\
ncidence_may_be_increasing_in/index.html?source=r_health